Activity of Anidulafungin in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)-β-D-Glucan Levels

被引：9

作者：

Ostrosky-Zeichner, Luis ^{[1
]}

Paetznick, Victor L.

Rodriguez, Jose

Chen, Enuo

Sheehan, Daniel J. ^{[2
]}

机构：

[1] Univ Texas Houston, Sch Med, Div Infect Dis, Lab Mycol Res, Houston, TX 77030 USA

[2] Pfizer Inc, New York, NY USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2009年 / 53卷 / 04期

关键词：

INVASIVE CANDIDIASIS; FLUCONAZOLE THERAPY; AMPHOTERICIN-B; CASPOFUNGIN; MICAFUNGIN; ECHINOCANDIN; EFFICACY; ISOLATE; TRIAL;

D O I：

10.1128/AAC.00955-08

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Experience with anidulafungin against Candida krusei is limited. Immunosuppressed mice were injected with 1.3 x 10(7) to 1.5 x 10(7) CFU of C. krusei. Animals were treated with saline, 40 mg/kg fluconazole, 1 mg/kg amphotericin B, or 10 and 20 mg/kg anidulafungin for 5 days. Anidulafungin improved survival and significantly reduced the number of CFU/g in kidneys and serum beta-glucan levels.

引用

页码：1639 / 1641

页数：3

共 22 条

[1]

[Anonymous], 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

[2]

Third Informational Supplement. CLSI document M27-S3, P28

[3] Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study [J].

Garey, Kevin W. ;

Turpin, Robin S. ;

Bearden, David T. ;

Pai, Manjunath P. ;

Suda, Katie J. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (05) :557-562

[4] Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study [J].

Garey, Kevin W. ;

Rege, Milind ;

Pai, Manjunath P. ;

Mingo, Dana E. ;

Suda, Katie J. ;

Turpin, Robin S. ;

Bearden, David T. .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) :25-31

[5] Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis [J].

Gumbo, Tawanda ;

Drusano, George L. ;

Liu, Weiguo ;

Ma, Lei ;

Deziel, Mark R. ;

Drusano, Michael F. ;

Louie, Arnold .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (11) :3695-3700

[6] Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy [J].

Hakki, Morgan ;

Staab, Janet F. ;

Marr, Meren A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) :2522-2524

[7] Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase [J].

Kahn, Jennifer Nielsen ;

Garcia-Effron, Guillermo ;

Hsu, Ming-Jo ;

Park, Steven ;

Marr, Kieren A. ;

Perlin, David S. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (05) :1876-1878

[8] Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia [J].

Krause, DS ;

Reinhardt, J ;

Vazquez, JA ;

Reboli, A ;

Goldstein, BP ;

Wible, M ;

Henkel, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2021-2024

[9] Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial [J].

Kuse, Ernst-Ruediger ;

Chetchotisakd, Ploenchan ;

da Cunha, Clovis Arns ;

Ruhnke, Markus ;

Barrios, Carlos ;

Raghunadharao, Digumarti ;

Sekhon, Jagdev Singh ;

Freire, Antonio ;

Ramasubramanian, Venkatasubramanian ;

Demeyer, Ignace ;

Nucci, Marcio ;

Leelarasamee, Amorn ;

Jacobs, Frederique ;

Decruyenaere, Johan ;

Pittet, Didier ;

Ullmann, Andrew J. ;

Ostrosky-Zeichner, Luis ;

Lortholary, Olivier ;

Koblinger, Sonja ;

Diekmann-Berndt, Heike ;

Cornely, Oliver A. .

LANCET, 2007, 369 (9572) :1519-1527

[10]

Marr Kieren A, 2004, Oncology (Williston Park), V18, P9

← 1 2 3 →